Aranesp® (darbepoetin alfa) administered once every 2 weeks (Q2W) maintains recommended haemoglobin (hb) in chronic kidney disease (ckd) patients on haemodialysis switched from weekly (QW) dosing

被引：0

作者：

Carrera, Fernando ^{[1
]}

Oliveira, Lino ^{[1
]}

Maia, Pedro ^{[1
]}

Mendes, Teresa ^{[1
]}

Ferreira, Candido ^{[1
]}

机构：

[1] Eurodial, Dialysis Unit, Leiria, Portugal

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2006年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

引用

页码：148 / 149

页数：2

共 50 条

[1] Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) effectively maintains haemoglobin (Hb) levels in dialysis
Mann, J
Kessler, M
Villa, G
Castelao, AM
Rasmussen, BF
Cruz, J
Hörl, WH
Wilkie, M
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V263 - V264
[2] Aranesp® (darbepoetin alfa) administered every other week (Q2W) corrects and maintains hemoglobin (Hb) in chronic kidney disease (CKD) patients
Hertel, J
Locay, H
Scarlata, D
Prathikanti, R
Audhya, P
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : A31 - A31
[3] Aranesp™ (darbepoetin alfa) administered once every other week (Q2W) corrects anemia in patients with chronic kidney disease (CKD)
Lindberg, JS
Navarro, J
Suranyi, M
Walker, R
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (04) : A22 - A22
[4] ALTERNATE: INTERIM RESULTS OF AN OBSERVATIONAL STUDY OF ARANESP® (DARBEPOETIN ALFA) ADMINISTERED ONCE EVERY 2 WEEKS (Q2W) IN DIALYSIS PATIENTS
Mcmahon, L.
Tolman, C.
Walsh, C.
NEPHROLOGY, 2008, 13 : A151 - A152
[5] Aranesp® (darbepoetin alfa) administered once monthly (QM) maintains hemoglobin (Hb) levels in chronic kidney disease (CKD) patients
Disney, A
de Jersey, P
Kirkland, G
Mantha, M
Charlesworth, J
Gallagher, M
Harris, D
Gock, H
Mangos, G
MacMillan, J
Viswalingam, A
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V254 - V255
[6] Switching darbepoetin alfa administration from weekly (QW) to once every 2 weeks (Q2W):: Does it influence the resistance index?
Molina, Manuel
Palacios, Maria Eugenia
Navarro, Maria Jose
De Gracia, Carmen
Garcia, Maria Angeles
Perez, Florentina
Ortuno, Tomas
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 353 - 353
[7] The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Carrera, Fernando
Oliveira, Lino
Maia, Pedro
Mendes, Teresa
Ferreira, Candido
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (10) : 2846 - 2850
[8] A phase 3, multicentre, randomised, double-blind, non-inferiority trial to evaluate the efficacy of Aranesp® (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp® once weekly (QW) in patients on haemodialysis (HD)
Locatelli, F
Villa, G
Backs, W
Del Pino, MD
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V260 - V260
[9] Aranesp® (darbepoetin alfa) administered every 2 weeks (Q2W) effectively maintains haemoglobin in patients receiving peritoneal dialysis:: Results of a pooled analysis of 8 European studies
Barril, G
Montenegro, JS
Ronco, C
Gokal, R
Bommer, J
Pais, MJ
Danielsen, H
Alfonso, JM
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V262 - V263
[10] Aranesp® (darbepoetin alfa) administered once monthly maintains hemoglobin levels in patients with chronic kidney disease (CKD).
Walczyk, M
Agarwal, A
Ling, B
Carroll, W
Liu, W
Brenner, R
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) : A38 - A38

← 1 2 3 4 5 →